Division: neurophotonics, neurorx
Dr. Louie is a translational scientist who advances new chemical and biological candidates through preclinical in vitro and animal evaluation, which ultimately progress these programs into human clinical trials. For these efforts, he has developed screening methods for each platform, and developed strategies to iteratively optimize the lead candidates into compounds possessing a balance between maximized stability, safety and pharmacokinetic profile. Additionally, Dr. Louie’s laboratory evaluate these types of drug platform in various disease models to determine the safety and efficacy of these types of treatment strategies.
His laboratory focuses on drug development for the treatment of infections, malignancies (e.g. HTLV-linked leukemia, Kaposi’s sarcoma), and neurodegenerative diseases. Efforts in the laboratory crosses a number of therapeutic areas include 1) drug development for novel agents that alter inflammatory response and accelerate healing, 2) development of new chemical entities targeting cellular adaptive mechanisms such as autophagy and endoplasmic reticulum stress, 3) development of Mas agonist for the treatment of ophthalmic and neurodegenerative diseases, and 4) development of light activated drug (Nanocaged) for traumatic brain injury and ophthalmologic injury.
Dr. Stan Louie is a clinical and translational pharmacologist with over two decades of clinical and drug development experience. Dr. Louie has focused on understanding inflammation and development of drugs against these chronic-debilitating disease. He graduated from UCSF in 1987, Dr. Louie continued his clinical training at California Pacific Medical Center (CPMC). After his residency training, Dr. Louie accepted a position at University of Southern California, where he began his academic career investigating cancer therapy, where he has explained into treating disease associated with chronic inflammation. This includes infections, malignancies and neurodegenerative diseases.
List of Publications:
Other web profiles: